We develop exosome-based delivery technology to bring powerful gene therapies to patients with life-threatening and currently incurable diseases.
ExoVectory is a biotechnology company developing exosomes as a next-generation delivery platform for precision gene therapy. At the core of the company is a proprietary method for loading large therapeutic DNA sequences into exosomes with exceptional efficiency, enabling treatments to travel throughout the body, cross the blood-brain barrier, and reach target cells without toxic side effects. Our mission is to transform exosomes into precision delivery vehicles for next-generation genetic therapies targeting untreatable diseases.
LEARN MORE
At the heart of ExoVectory’s platform is ExoVec — a proprietary exosome loading and targeting technology. Using our unique Exosome Loading Proteins (ELPs), ExoVec packages therapeutic DNA of up to 36,000 base pairs, outperforming well-known gene therapy vectors, and enabling delivery of a wide range of payloads, from CRISPR-Cas editing tools to cancer-killing viral genomes. Our loaded exosomes offer two further advantages: they penetrate deep into tumour masses and remain invisible to the immune system, avoiding the antibody responses that limit other delivery systems. Combined with surface-level targeting proteins, this makes our platform uniquely precise, powerful and scalable towards the clinic.
ExoVectory is advancing ExoVec through two therapeutic programmes, targeting cancers and genetic diseases where existing treatments fall short.
Our ex vivo therapeutic programme uses ExoVec to engineer CAR/TCR T-cells for the treatment of cancer, focusing on primary central nervous system lymphoma (PCNSL) — a rare and aggressive brain cancer with limited treatment options and a 3-year survival rate of just 30% — as our lead indication.
Our in vivo programme is developing ExoVec as a systemic gene therapy delivery platform for cardiac and CNS diseases, where delivering large therapeutic DNA constructs safely to the target tissue remains the central unsolved challenge in the field.
ExoVectory is built by passionate individuals who believe exosomes can change the way we treat diseases. Our team has grown to include specialists in exosome biology, gene therapy, production and business development, supported by a network of well-known scientific advisors and senior biotech entrepreneurs who bring deep industry expertise to our mission.
MEET THE TEAM
ExoVectory combines world-class expertise in exosome biology, proprietary loading and targeting technology, and a growing track record of academic and industry collaborations. Whether you are looking to explore ExoVec as a delivery solution, co-develop a therapeutic programme, or access our exosome platform for your own research, we are open to partnerships that bring new treatments closer to patients.
CONTACT US
large DNA payload
